Kane Biotech Announces Exclusive License and Distribution Agreement with Dechra

Posted in: Press Releases

WINNIPEG, Manitoba – March 6, 2017 – Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”) is pleased to announce that it has entered into an exclusive license and distribution agreement (the “License Agreement”) with Dechra Veterinary Products LLC (“Dechra”), a wholly-owned subsidiary of Dechra Pharmaceuticals PLC (LSE:DPH). Dechra is an international specialty veterinary pharmaceuticals products company with expertise in the development, manufacture and sales and marketing of high quality products for veterinarians worldwide. Pursuant to the License Agreement, Kane Biotech has agreed to exclusively license its StrixNB™ and DispersinB® oral care and dermatology products to Dechra for commercialization in the North American veterinary market.

Under the terms of this 10-year Agreement, Kane Biotech will receive an upfront payment upon signing along with a series of potential payments linked to various commercial milestones to a combined maximum of USD $2.0 million.  In addition, Kane Biotech will receive an ongoing royalty on net sales of its Products by Dechra in North America, subject to certain minimum annual royalty payments by Dechra to Kane Biotech.  Terms of the Agreement are confidential between the parties and further financial details are not disclosed.

Mark Ahrens-Townsend, President and CEO of Kane Biotech, commented, “We are pleased to have concluded this commercial partnership with Dechra for North America. Dechra represents an ideal commercial partner in the specialty veterinarian market for Kane Biotech’s StrixNB and DispersinB oral care and dermatology products given its existing commercial footprint, sales force, and synergies with its current product portfolio. Dechra is a highly successful company with proven expertise in developing market-leading brands in the specialty veterinarian market and we are excited about the growth prospects for our StrixNB and DispersinB brands under this arrangement. This license agreement represents an important validation of Kane Biotech’s research and development and intellectual property programs, and the market value of our products and technologies by a leading veterinary pharmaceutical company.”

Mike Eldred, President of Dechra Veterinary Products LLC commented, “The entire Dechra team is pleased to have concluded this wide-ranging commercial partnership with Kane Biotech.  The StrixNB oral care and DispersinB dermatology products and technologies provide Dechra with a significant opportunity to build market share in these strategic market segments.  The technology developed by Kane Biotech is innovative and highly differentiated, which will provide Dechra the opportunity to provide veterinarians with efficacious products to resolve many of the day-to-day challenges in their clinics.  We look forward to a long and successful partnership with Kane Biotech.”

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, and foodborne bacterial infections.  According to the United States National Institutes of Health biofilms are estimated to be responsible for 80% of all human bacterial infections and cost individuals, industry, governments and hospitals billions of dollars each year.  As such, there is significant interest in safe and effective products that can combat the biofilm problem.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Corporation has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions.    StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc.   The Corporation is listed on the TSX Venture Exchange under the symbol “KNE”.

For more information, please contact:

Mark Ahrens-Townsend

President & CEO

Kane Biotech Inc.
204-477-7592 phone
204-474-7552 fax